# (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

> **NCT05767879** · PHASE2 · UNKNOWN · sponsor: **Leiden University Medical Center** · enrollment: 28 (estimated)

## Conditions studied

- Melanoma Stage III
- In-Transit Metastasis of Cutaneous Melanoma

## Interventions

- **DRUG:** Encorafenib + Binimetinib

## Key facts

- **NCT ID:** NCT05767879
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2023-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05767879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05767879, "(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05767879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*